Synthesis and spectrum of the neoglycoside ACHN-490

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 11, 2010, Pages 4636-4642

  Aggen, James B ^a   Armstrong, Eliana S ^a   Goldblum, Adam A ^a   Dozzo, Paola ^a   Linsell, Martin S ^a   Gliedt, Micah J ^a   Hildebrandt, Darin J ^a   Feeney, Lee Ann ^a   Kubo, Aya ^a   Matias, Rowena D ^a   Lopez, Sara ^a   Gomez, Marcela ^a   Wlasichuk, Kenneth B ^a   Diokno, Raymond ^a   Miller, George H ^a   Moser, Heinz E ^a  

^a Achaogen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; SISOMICIN;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; DRUG STRUCTURE; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEALTH CARE FACILITY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; ENTEROBACTERIACEAE; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SISOMICIN;

EID: 77957764600     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00572-10     Document Type: Article

References (24)

1. Aggen, J., E. Armstrong, A. Goldblum, P. Dozzo, M. Linsell, M. Gliedt, et al. 2009. Synthesis, structure, and in vitro activity of the neoglycoside ACHN-490, poster F1-840. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
2. Armstrong, E., D. Biedenbach, R. Jones, and G. Miller. 2009. Surveying aminoglycoside resistance mechanisms: a tool for the development of neoglycosides, poster P-643. Abstr. 19th Eur. Congr. Clin. Microbiol. Infect. Dis. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
3. Biedenbach, D., R. Jones, G. Miller, and E. Armstrong. 2009. Ten-year trend in aminoglycoside resistance from a worldwide collection of gram-negative pathogens (1998-2007), poster P-636. Abstr. 19th Eur. Congr. Clin. Microbiol. Infect. Dis. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
4. Chambers, H. F. 2006. Aminoglycosides, p. 1155-1171. In L. Brunton, J. Lazo, and K. Parker (ed.), Goodman & Gilman's the pharmacological basis of therapeutics, 11th ed. McGraw-Hill, New York, NY.
5. Clinical and Laboratory Standards Institute. 2009. M100-S19. Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Doi, Y., and Y. Arakawa. 2007. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin. Infect. Dis. 45:88-94.
7. Drusano, G. L., P. G. Ambrose, S. M. Bhavnani, J. S. Bertino, A. N. Nafziger, and A. Louie. 2007. Back to the future: using aminoglycosides again and how to dose them optimally. Clin. Infect. Dis. 45:753-760.
8. Hawkey, P. M., and A. M. Jones. 2009. The changing epidemiology of resistance. J. Antimicrob. Chemother. 64(Suppl. 1):i3-i10.
9. Hawser, S. P., S. K. Bouchillon, D. J. Hoban, and R. E. Badal. 2009. In vitro susceptibilities of aerobic and facultative anaerobic gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study. Int. J. Antimicrob. Agents 34:585-588.
10. Hermann, T. 2007. Aminoglycoside antibiotics: old drugs and new therapeutic approaches. Cell. Mol. Life Sci. 64:1841-1852.
11. Jana, S., and J. K. Deb. 2006. Molecular understanding of aminoglycoside action and resistance. Appl. Microbiol. Biotechnol. 70:140-150.
12. Jones, R. N., M. L. Beach, and M. A. Pfaller. 2001. Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different! Diagn. Microbiol. Infect. Dis. 41:161-163.
13. Klastersky, J., R. Cappel, and D. Daneau. 1972. Clinical significance of in vitro synergism between antibiotics in gram-negative infections. Antimicrob. Agents Chemother. 2:470-475.
14. Lee, S., and C. Cheong. 2001. Selective reactions of reactive amino groups in polyamino compounds by metal-chelated or -mediated methods. Tetrahedron 57:4801-4815. (Pubitemid 32519620)
15. Miller, G. H., F. J. Sabatelli, R. S. Hare, Y. Glupczynski, P. Mackey, D. Shlaes, et al. 1997. The most frequent aminoglycoside resistance mechanisms. Changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups. Clin. Infect. Dis. 24(Suppl. 1):S46-S62.
16. Miller, G. H., F. J. Sabatelli, L. Naples, R. S. Hare, K. J. Shaw, et al. 1995. The most frequently occurring aminoglycoside resistance mechanisms: combined results of surveys in eight regions of the world. Aminoglycoside Resistance Study Groups. J. Chemother. 7(Suppl. 2):17-30.
17. Nagabhushan, T. L. 14 December 1976. U.S. patent 3,997,524.
18. Nam, G., S. H. Kim, J.-H. Kim, J.-H. Shin, and E.-S. Jang. 2002. An efficient and selective 1-N-monoethylation of sisomicin: process development of netilmicin. Org. Proc. Res. Dev. 6:78-81.
19. Rossi, F., F. Baquero, P. R. Hsueh, D. L. Paterson, G. V. Bochicchio, T. A. Snyder, et al. 2006. In vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J. Antimicrob. Chemother. 58:205-210.
20. Rybak, M. J., and B. J. McGrath. 1996. Combination antimicrobial therapy for bacterial infections. Guidelines for the clinician. Drugs 52:390-405.
21. Shaw, K. J., P. N. Rather, R. S. Hare, and G. H. Miller. 1993. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol. Rev. 57:138-163.
22. Sobel, M. L., G. A. McKay, and K. Poole. 2003. Contribution of the MexXY multidrug transporter to aminoglycoside resistance in Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 47:3202-3207.
23. Waitz, J. A., G. H. Miller, E. Moss, Jr., and P. J. Chiu. 1978. Chemotherapeutic evaluation of 5-episisomicin (Sch 22591), a new semisynthetic aminoglycoside. Antimicrob. Agents Chemother. 13:41-48.
24. Wright, G. D. 1999. Aminoglycoside-modifying enzymes. Curr. Opin. Microbiol. 2:499-503.